One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

Glioblastoma remains one of the most stubbornly difficult forms of cancer to treat. It is the most common and most aggressive malignant brain tumour, and only half of people survive 12 months after ...

Critical gaps in understanding how species respond to environmental change limit our capacity to address conservation risks in a timely way. Here, we examine the direct and interactive effects of key ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Genetic modifications in reproductive cells, such as eggs, sperm, or embryos, are commonly referred to as germline editing and are heritable. 1 CRISPR-Cas 9, which stands for clustered regularly ...